Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib plus docetaxel and prednisone versus placebo plus docetaxel and prednisone in hormone-refractory prostate cancer
2005-004378-25Phase 2Terminated
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Dec 2005
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in castration-resistant prostate cancer (CRPC) comparing Sorafenib + Taxotere + prednisone with Placebo + Taxotere + prednisone (2 arms). Primary endpoints: Time to progression and Progression-free survival by cPSA. Started Dec 2005; status: terminated.
02
Drugs
sorafenibdocetaxelprednisone
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2005-004378-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004378-25.